During nearly two years of preparation prior to company’s establishment, business model, commercialization strategy and legal protection of invention were developed together with the University and research team. In July 2015 company was officially established with the participation of University’s special purpose vehicle (SPV), R&D team – patent creators and implementation team, experienced in securing external funding and managing innovative projects.

PolTREG is the only entity entitled to implementing the research findings in the area of T-regulatory lymphocytes and using their growth method for clinical use.